Anti-PD1/PDL1 induced psoriasis

Current Problems in Cancer

Volumn 41, Issue 6, 2017, Pages 407-412

  Voudouri, Dimitra ^a   Nikolaou, Vasiliki ^a   Laschos, Konstantinos ^b   Charpidou, Andriani ^a   Soupos, Nikolaos ^b   Triantafyllopoulou, Ioanna ^a   Panoutsopoulou, Ioanna ^a   Aravantinos, Gerasimos ^b   Syrigos, K ^a   Stratigos, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGII ANARGIRI CANCER HOSPITAL   (Greece)

Author keywords

Anti PD1; Durvalumab; Nivolumab; Pembrolizumab; Psoriasis

Indexed keywords

ANTINEOPLASTIC AGENT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CISPLATIN; DURVALUMAB; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISOLONE; STEROID; THYROTROPIN; THYROXINE; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ANKLE ARTHRITIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELBOW; FAMILY HISTORY; FEMALE; GEL; GUTTATE PSORIASIS; HAND; HUMAN; HYPERKERATOSIS; KNEE; KNEE ARTHRITIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAINTENANCE CHEMOTHERAPY; MALE; MEDICAL HISTORY; METASTASIS; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; NAIL PSORIASIS; NARROW BAND IMAGING; NON SMALL CELL LUNG CANCER; PAPILLARY CARCINOMA; PARAAORTIC LYMPH NODE; PHOTOTHERAPY; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; REMISSION; SCALP; SKIN BIOPSY; SKIN DEFECT; SKIN ULCER; STEROID THERAPY; SYSTEMIC THERAPY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TONSIL CARCINOMA; TOPICAL TREATMENT; TRANSITIONAL CELL CARCINOMA; ULTRAVIOLET B RADIATION; WRIST; ANAMNESIS; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PROCEDURES; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PSORIASIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS;

EID: 85033690916     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2017.10.003     Document Type: Article

References (9)

1. Belum, V.R., Benhuri, B., Postow, M.A., et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60 (2016), 12–25.
2. Hwang, S.J., Carlos, G., Wakade, D., et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single—institution cohort. J Am Acad Dermatol 74:3 (2016), 455–461.
3. Bonigen, J., Raynaud-Donzel, C., Hureaux, J., et al. Anti-PD1 induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 31:5 (2017), e254–e257.
4. Kato, Y., Otsuka, A., Miyachi, Y., Kabashima, K., Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 30 (2016), e89–e91.
5. He, J., Hu, Y., Hu, M., Li, B., Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep, 5, 2015, 13110, 10.1038/srep13110.
6. Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. J Annu Rev Immunol 26 (2008), 677–704, 10.1146/annurev.immunol.26.021607.090331.
7. Velcheti, V., Schalper, K.A., Carvajal, D.E., et al. Programmed death ligand-1 expression in non-small cell lung cancer. J Lab Invest 94:1 (2014), 107–116, 10.1038/labinvest.2013.130.
8. Monteleone, G., Pallone, F., Macdonald, T.T., Chimenti, S., Costanzo, A., Psoriasis: from pathogenesis to novel therapeutic approaches. Clin Sci 120:1 (2011), 1–11, 10.1042/CS20100163.
9. Chong, H.T., Kopecki, Z., Cowin, A.J., Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis. Biomed Res Int, 2013, 2013, 168321, 10.1155/2013/168321.